(3E)-2-methylhexa-1,3,5-trien-3-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (3E)-2-methylhexa-1,3,5-trien-3-amine
• 化学式: C₇H₁₁N
• 分子量: 109.17
• InChiKey: NGDIXCQQZNLNIA-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS<br/>[FR] AGENTS DE DÉGRADATION TRICYCLIQUES D'IKAROS ET D'AIOLOS
  申请人：C4 THERAPEUTICS INC

  公开号：WO2020210630A1

  公开（公告）日：2020-10-15

  Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

  三环脑蛋白结合剂通过泛素蛋白酶体途径降解Ikaros或Aiolos以用于治疗应用的描述。
• [EN] HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION COMME LIGANDS DE LA DOPAMINE D1
  申请人：PFIZER

  公开号：WO2014072881A1

  公开（公告）日：2014-05-15

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

  本发明部分提供了化合物I的公式：及其药学上可接受的盐和N-氧化物；制备的过程和中间体；以及其组合物和用途。本发明进一步提供了具有减少D1R耐受性的D1激动剂，相对于多巴胺具有减少β-阿雷斯汀招募活性的D1激动剂，当结合到D1R时与D1R的Ser188显著相互作用但与Ser202的相互作用不显著的D1激动剂，当结合到D1R时与D1R的Asp103相互作用较弱并且与Ser198相互作用较弱的D1激动剂，以及它们的用途。
• PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES
  申请人：THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：US20180148414A1

  公开（公告）日：2018-05-31

  The invention generally relates to methods of making substituted arenes via direct C—H amination. More specifically, methods of making para- and ortho-substituted arenes via direct C—H amination are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

  公开号：US20200239454A1

  公开（公告）日：2020-07-30

  Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, said compound has good RORγ inhibitory activity and is expected to be used for treating diseases mediated by a RORγ receptor in mammals.
• [EN] IMIDAZOLYLAMIDE DERIVATIVE<br/>[FR] DÉRIVÉ D'IMIDAZOLYLAMIDE<br/>[JA] イミダゾリルアミド誘導体
  申请人：SUMITOMO DAINIPPON PHARMA CO LTD

  公开号：WO2017146128A1

  公开（公告）日：2017-08-31

  本発明は、優れたがん細胞スフィア形成能抑制作用を示し、経口投与可能な抗腫瘍剤として有用な、式（１）で表されるイミダゾルアミド誘導体またはその製薬学的に許容される塩に関する。 ［式中、環Ｑ１は、Ｃ６－１０アリール基等を表し；ｍは、０、１、２、３、４または５を表し；Ｒ３は、複数ある場合は独立して、ハロゲン原子等を表し；Ｒ１およびＲ２は、独立して、水素原子等を表し；Ｗ１は、Ｃ１－４アルキレン基（該基は、１～３個のフッ素原子またはＣ３－７シクロアルキルで置換されていてもよい）を表し；Ｗ２は、－ＮＲ４ａＣ（Ｏ）－等（ここにおいて、Ｒ４ａは、水素原子またはＣ１－６アルキル基を表す）を表し；環Ｑ２は、Ｃ６－１０アリール基等を表す］